155 related articles for article (PubMed ID: 25361604)
1. MALT1 protease: equilibrating immunity versus tolerance.
Bertossi A; Krappmann D
EMBO J; 2014 Dec; 33(23):2740-2. PubMed ID: 25361604
[TBL] [Abstract][Full Text] [Related]
2. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
4. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
5. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
6. A two-step activation mechanism of MALT1 paracaspase.
Staal J; Beyaert R
J Mol Biol; 2012 May; 419(1-2):1-3. PubMed ID: 22426126
[No Abstract] [Full Text] [Related]
7. MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.
Schmitt A; Grondona P; Maier T; Brändle M; Schönfeld C; Jäger G; Kosnopfel C; Eberle FC; Schittek B; Schulze-Osthoff K; Yazdi AS; Hailfinger S
J Invest Dermatol; 2016 Apr; 136(4):788-797. PubMed ID: 26767426
[TBL] [Abstract][Full Text] [Related]
8. Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
Juilland M; Thome M
Curr Opin Hematol; 2016 Jul; 23(4):402-9. PubMed ID: 27135977
[TBL] [Abstract][Full Text] [Related]
9. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
10. The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Brüstle A; Brenner D; Knobbe CB; Lang PA; Virtanen C; Hershenfield BM; Reardon C; Lacher SM; Ruland J; Ohashi PS; Mak TW
J Clin Invest; 2012 Dec; 122(12):4698-709. PubMed ID: 23114599
[TBL] [Abstract][Full Text] [Related]
11. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination.
Mc Guire C; Wieghofer P; Elton L; Muylaert D; Prinz M; Beyaert R; van Loo G
J Immunol; 2013 Mar; 190(6):2896-903. PubMed ID: 23401595
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
13. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.
Noels H; van Loo G; Hagens S; Broeckx V; Beyaert R; Marynen P; Baens M
J Biol Chem; 2007 Apr; 282(14):10180-9. PubMed ID: 17287209
[TBL] [Abstract][Full Text] [Related]
14. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.
Nakaya M; Xiao Y; Zhou X; Chang JH; Chang M; Cheng X; Blonska M; Lin X; Sun SC
Immunity; 2014 May; 40(5):692-705. PubMed ID: 24792914
[TBL] [Abstract][Full Text] [Related]
16. A role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma.
Bonsignore L; Passelli K; Pelzer C; Perroud M; Konrad A; Thurau M; Stürzl M; Dai L; Trillo-Tinoco J; Del Valle L; Qin Z; Thome M
Leukemia; 2017 Mar; 31(3):614-624. PubMed ID: 27538487
[TBL] [Abstract][Full Text] [Related]
17. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface.
Cabalzar K; Pelzer C; Wolf A; Lenz G; Iwaszkiewicz J; Zoete V; Hailfinger S; Thome M
PLoS One; 2013; 8(8):e72051. PubMed ID: 23977204
[TBL] [Abstract][Full Text] [Related]
18. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
20. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.
Varfolomeev E; Wayson SM; Dixit VM; Fairbrother WJ; Vucic D
J Biol Chem; 2006 Sep; 281(39):29022-9. PubMed ID: 16891304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
